Clinical Trial

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

Study acronym: Peri-E
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 14, 2024 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective, single-arm, single-center Phase II trial, aiming to investigate efficacy and safety of neoadjuvant chemotherapy sequentially combined with sintilimab in resectable EGFR-mutant stage II-IIIB non-squamous NSCLC patients
Trial Details
NCT Number NCT06688656
Lead Sponsor Shanghai Chest Hospital
Conditions Lung Cancer
Enrollment 30 participants
Start Date 2025-03-31
Primary Completion 2026-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-14